IL311639A - Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseases - Google Patents
Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseasesInfo
- Publication number
- IL311639A IL311639A IL311639A IL31163924A IL311639A IL 311639 A IL311639 A IL 311639A IL 311639 A IL311639 A IL 311639A IL 31163924 A IL31163924 A IL 31163924A IL 311639 A IL311639 A IL 311639A
- Authority
- IL
- Israel
- Prior art keywords
- antigen
- binding fragment
- cognitive
- assessment
- disease
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims 13
- 238000000034 method Methods 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 239000012634 fragment Substances 0.000 claims 28
- 208000010877 cognitive disease Diseases 0.000 claims 23
- 108010056102 CD100 antigen Proteins 0.000 claims 18
- 102100027744 Semaphorin-4D Human genes 0.000 claims 18
- 230000001149 cognitive effect Effects 0.000 claims 16
- 208000028698 Cognitive impairment Diseases 0.000 claims 13
- 208000023105 Huntington disease Diseases 0.000 claims 13
- 230000009760 functional impairment Effects 0.000 claims 10
- 208000027061 mild cognitive impairment Diseases 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 102100034384 Plexin-B1 Human genes 0.000 claims 3
- 101710100559 Plexin-B1 Proteins 0.000 claims 3
- 102100034383 Plexin-B2 Human genes 0.000 claims 3
- 101710100551 Plexin-B2 Proteins 0.000 claims 3
- 208000011235 central nervous system lupus Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1124—Determining motor skills
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/168—Evaluating attention deficit, hyperactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2505/00—Evaluating, monitoring or diagnosing in the context of a particular type of medical care
- A61B2505/09—Rehabilitation or training
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Developmental Disabilities (AREA)
- Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Educational Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Artificial Intelligence (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Signal Processing (AREA)
- Genetics & Genomics (AREA)
- Social Psychology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/052142 WO2023048726A1 (fr) | 2021-09-27 | 2021-09-27 | Profilage prédictif de résultats pour l'utilisation d'une molécule de liaison anti-sémaphorine-4d pour traiter des troubles neurodégénératifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311639A true IL311639A (en) | 2024-05-01 |
Family
ID=78463919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311639A IL311639A (en) | 2021-09-27 | 2021-09-27 | Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseases |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2024535403A (fr) |
| KR (1) | KR20240063995A (fr) |
| AU (1) | AU2021465518A1 (fr) |
| CA (1) | CA3231551A1 (fr) |
| IL (1) | IL311639A (fr) |
| MX (1) | MX2024003883A (fr) |
| WO (1) | WO2023048726A1 (fr) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP4095753B2 (ja) | 2000-03-30 | 2008-06-04 | 株式会社ルネサステクノロジ | コンピュータ読み取り可能な記憶媒体、および半導体装置の設計方法 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1442749A1 (fr) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Utilisation d'un anticorps anti-CD100 pour le traitement et le diagnostic d'une maladie inflammatoire du système nerveux central |
| WO2008100995A1 (fr) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Anticorps humains anti-cd100 |
| KR101754433B1 (ko) | 2009-05-08 | 2017-07-05 | 백시넥스 인코포레이티드 | 항-ｃｄ100 항체 및 이의 사용 방법 |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CN110325213A (zh) * | 2017-02-22 | 2019-10-11 | 瓦西尼斯公司 | 神经退行性或神经炎性疾病中胶质细胞活化的早期检测 |
| SG11201909466RA (en) | 2017-05-05 | 2019-11-28 | Vaccinex Inc | Human anti-semaphorin 4d antibody |
-
2021
- 2021-09-27 AU AU2021465518A patent/AU2021465518A1/en active Pending
- 2021-09-27 CA CA3231551A patent/CA3231551A1/fr active Pending
- 2021-09-27 MX MX2024003883A patent/MX2024003883A/es unknown
- 2021-09-27 KR KR1020247013488A patent/KR20240063995A/ko active Search and Examination
- 2021-09-27 WO PCT/US2021/052142 patent/WO2023048726A1/fr active Application Filing
- 2021-09-27 JP JP2024518774A patent/JP2024535403A/ja active Pending
- 2021-09-27 IL IL311639A patent/IL311639A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023048726A1 (fr) | 2023-03-30 |
| CA3231551A1 (fr) | 2023-03-30 |
| AU2021465518A1 (en) | 2024-05-02 |
| KR20240063995A (ko) | 2024-05-10 |
| JP2024535403A (ja) | 2024-09-30 |
| MX2024003883A (es) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huijbers et al. | The expanding field of IgG4‐mediated neurological autoimmune disorders | |
| Frank et al. | TREM2 is upregulated in amyloid plaque‐associated microglia in aged APP23 transgenic mice | |
| JP2017502920A5 (fr) | ||
| Temiz et al. | Inflammatory myopathies with mitochondrial pathology and protein aggregates | |
| IL275720B (en) | Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders | |
| Strekalova et al. | Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes | |
| JP2019059786A5 (fr) | ||
| RU2019122337A (ru) | Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях | |
| US11022618B2 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43 | |
| JP2020510845A5 (fr) | ||
| RU2013120544A (ru) | Фармацевтическая композиция | |
| RU2014144331A (ru) | Гуманизированное тау-антитело | |
| Das et al. | CCL20-CCR6 axis modulated traumatic brain injury-induced visual pathologies | |
| JP5785873B2 (ja) | Ｔ細胞活性化阻害剤、これを含有する医薬組成物およびｔ細胞活性化阻害物質のスクリーニング方法 | |
| Qin et al. | Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients | |
| Balestra et al. | Antibodies against neuronal nicotinic receptor subtypes in neurological disorders | |
| IL311639A (en) | Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseases | |
| Hüfner et al. | Neurology issues in schizophrenia | |
| Hermosillo-Romo et al. | Neuropsychiatric involvement in systemic lupus erythematosus | |
| Hanaoka et al. | Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV | |
| Gupta et al. | Growing spectrum of autoimmune nodopathies | |
| Cervantes González et al. | Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration | |
| Estades Ayuso et al. | TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains | |
| Yamakawa et al. | Antibodies to the α3 subunit of the ganglionic-type nicotinic acetylcholine receptors in patients with autoimmune encephalitis | |
| Zhou et al. | Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis |